Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Apellis Pharmaceuticals, Leeds, UK, talks on the role of measurable residual disease (MRD) in decision-making in chronic lymphocytic leukemia (CLL). Whilst MRD has been used as a key endpoint in many clinical trials, no real-world evidence is indicating that MRD should be used to guide therapy in CLL. According to Prof. Hillmen, in the future, MRD will be used as a tool to define the duration of therapy and to predict outcomes in clinical practice. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

свернуть